http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Combinational therapy in triple negative breast cancer
Front cover -- Half title -- Copyright -- Contents -- Contributors -- About the author -- Foreword -- Preface -- Acknowledgment -- Chapter 1 -- Triple-negative breast cancer -- an aggressive subtype of breast cancer -- Introduction -- Triple-negative breast cancer (TNBC) -- TNBC histological classification -- TNBC molecular classification -- BL-1 and BL-2 -- M subtype -- MSL subtype -- IM subtype -- LAR subtype -- TNBC and BRCA -- Triple-negative breast cancer risk factors and epidemiology -- Current diagnostic options for triple-negative breast cancer -- Mammography -- Ultrasound
Magnetic resonance imaging (MRI) -- Future diagnostic options for TNBC -- Blood-based liquid biopsy -- Circulating tumor nucleic acids (ctNAs) -- Exosomes -- Immuno-positron emission tomography (PET) -- Nanobiosensor -- nCounter breast cancer 360 panel -- Digital polymerase chain reaction (dPCR) -- Triple-negative breast cancer's prognostic implications -- Somatic genomic mutations in TNBC -- Epigenetic modifications in TNBC -- Methylation of DNA in triple-negative breast cancer -- Relation between DNA methylation and TNBC progression -- Role of long noncoding RNAs in TNBC
Role of MicroRNA in TNBC -- Role of histone modifications in TNBC -- Summary -- References -- Chapter 2 -- Novel biomarkers in triple-negative breast cancer -- role and perspective -- Introduction -- Triple-negative breast cancer: Genetic markers -- TP53 -- BRCA1/2 -- PI3K pathway -- Androgen receptor -- BCL2 gene -- Cyclin-dependent kinases -- Triple-negative breast cancer: Novel biomarkers -- EGFR -- VEGF -- C-kit and basal cytokeratins -- TOP-2A -- Ki67 -- PARP -- Heat shock protein 90 -- Cox-2 -- Epigenetic modifications in TNBC as novel biomarkers -- Tissue miRNAs as biomarkers in TNBC